

BioBusiness Asia 2009

Company Name	TCM Biotech International Corp.		
Presenter	Ya-Chun Wang	Title	EVP
Address	7F., No. 11, Lane 35, Jihu Rd., Neihu District, Taipei 114 Taiwan, R.O.C		
Website	http://www.tcmbio.com/english/main.htm		
No. of employee	35	Year of foundation	1998
Company Categories	<input type="checkbox"/> Novel Therapeutics <input type="checkbox"/> Genomics <input checked="" type="checkbox"/> Pharmaceuticals <input type="checkbox"/> R&D Service <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other _____		
Paid-in Capital	NT\$250million		
Company Stage	<input type="checkbox"/> Seed <input type="checkbox"/> Start up <input checked="" type="checkbox"/> Expansion <input type="checkbox"/> Mezzanine		
Company Overview	<p>TCM Biotech International Corp. was established in 1998 as a company specializing in innovative Chinese herbal drug development. In the years since, we have been steadily building up our research, development and manufacturing capabilities, with the establishment of a modern drug R&D center, as well as a fermentation and extraction pilot plant. From the lab to store shelf, TCM Biotech takes each product from the earliest stages of discovery and development through to testing, manufacturing, scale up, and marketing. The company already has a number of successful products on the market derived from Chinese herbal drugs, and is constantly working to develop innovative new products for the benefit of your health.</p>		
Company History	<p>2008 <u>Oct</u></p> <ul style="list-style-type: none"> • Obtained Innovation Award from the Ministry of Economic Affairs for TCM-700C and "PHC enriched." <p><u>Jun</u></p> <ul style="list-style-type: none"> • Obtained Health Food Certification from DOH for "PHC enriched." <p>2007 <u>Apr</u></p> <ul style="list-style-type: none"> • The Ministry of Economic Affairs approved the grant of NT\$19,340,000 for Phase II Clinical trial studies of TCM-700C through ITDP program 		

	<p>2006</p> <p><u>Dec</u></p> <ul style="list-style-type: none"> Submitted Application of “PHC enriched“ as Health Food to DOH <p><u>Nov</u></p> <ul style="list-style-type: none"> Obtained Symbol of National Quality for "PHC enriched". Delivered speech and announced the excellent R&D result of TCM-700C formula, an adjuvant agent for hepatitis C, in Grand Hyatt, Taipei. <p><u>May</u></p> <ul style="list-style-type: none"> Granted 20-year patent of TCM-700C formula, an adjuvant agent for hepatitis C, in China. (No. ZL200310101281.1) Granted 20-year patent of TCM-700C formula, an adjuvant agent for hepatitis C, in Taiwan. (Type I, No. 258373) Applying for IND of TCM-700C formula in China. <p><u>Jan</u></p> <ul style="list-style-type: none"> Approved by Taiwan DOH for IND - Phase II clinical trial of TCM-700C formula, an adjuvant agent for hepatitis C.
	<p>2005</p> <p><u>Dec</u></p> <ul style="list-style-type: none"> Laboratory obtained renewal of ISO9001 certificate. <p><u>Apr</u></p> <ul style="list-style-type: none"> Applying registration of health food for "PHC enriched". <p><u>Mar</u></p> <ul style="list-style-type: none"> Developed health food product, "PHC enriched" (own-brand health food product similar to TCM-700C formula), and experiment begun for evaluation of liver protection followed national "Health Food" regulations.
	<p>2004</p> <p><u>Oct</u></p> <ul style="list-style-type: none"> Approval by US FDA for IND - Phase II clinical trial of TCM-700C formula. <p><u>Jun</u></p> <ul style="list-style-type: none"> Patent obtained in Taiwan for TCM Biotech's proprietary DNA sequence and analysis method for Cordyceps Sinensis (No. 205527). <p><u>May</u></p> <ul style="list-style-type: none"> Capital increased to NT\$125 million (US\$3.8 million). Merger with SC Biotech, a Taiwanese biotechnology company, as 100 percent owned subsidiary. <p><u>Mar</u></p> <ul style="list-style-type: none"> Laboratory facility established in Neihu Science Park, Taipei, Taiwan

<p>Main Products/ Service & Niche of Products/ Service</p>	<p>KEY PRODUCT LEAD</p> <ul style="list-style-type: none"> • TCM-700C <p>HCV treatment adjuvant therapy TCM-700C was approved for Phase II clinical trials in Taiwan by both the US Food and Drug Administration (FDA) and Taiwan's Department of Health (DOH). TCM enrolled patients for this clinical trial beginning early 2007.</p> <ul style="list-style-type: none"> • Hepa C <p>The product was granted a “SNQ” national quality mark from Institute for Biotechnology and Medicine Industry and a “Healthy Food” certificate mark (File number: A00127, please refer to attachment 3 in the email) from Department of Health, Executive Yuan, R.O.C. (Taiwan).</p> <p>Efficacy</p> <ol style="list-style-type: none"> 1. Decrease the serum GOT and GPT levels 2. Decrease the collagen formation in liver tissues 3. Increase Anti-oxidant bioactivity of hepatic Catalase、SOD、GHS-Px and GR 4. Decrease the fibrosis symptom of liver from the view of pathological section <p>Major services</p> <p>1.Functional Ingredients Supply</p> <p>The main functional ingredients currently supplied by TCM Biotech include Cordyceps sinensis, Rhodiola, Antrodia Camphorata, and many others. To know more about the technical specifications of these miraculous ingredients please refer to Ingredients Enquiry.</p> <p>2.ODM/OEM</p> <p>TCM Biotech is fully capable of providing total solutions for functional product development and production and has earned great reputations from its customers</p> <p>3.Biochemical Testing</p> <p>Owning an ISO-9001 certified laboratory TCM Biotech also provides services of examining heavy metals, microelements, and microorganisms, as well as general biochemical testing and HPLC analyses.</p>
<p>Market Potentials</p>	<ol style="list-style-type: none"> 1. Adjuvant of hepatitis C conventional treatment 2. Protection/prevention from the damage of Liver diseases
<p>Company Core Competence or Competitive Advantage</p>	<ol style="list-style-type: none"> 1. Strain screening and mass fermentation process development 2. Botanical new drug development platform
<p>Partnering Objectives</p>	<ol style="list-style-type: none"> 1. Technical transfer and/or co-development of botanical new drug, TCM-700C for global market. 2. Distribution and/or co-marketing of functional food, Hepa C, for global market.

